Assessing the impact of long-term inhaled corticosteroid therapy on patients with COVID-19 and coexisting chronic lung disease: A multicenter retrospective cohort study.
Adela Pina BelmonteManuel MadrazoLaura PilesManuel Rubio-RivasLucía de Jorge HuertaMaría Gómez AntúnezJuan Francisco López CaleyaFrancisco Arnalich FernándezMartin Gericó-AseguinolazaPaula Maria Pesqueira FontanNicolás RhymanMarina Prieto DehesaJuan Luis Romero CabreraGema María García GarcíaGonzalo García-CasasolaAne Labirua-Iturburu RuizFrancisco Javier Carrasco-SánchezSara Martínez HernándezMaria de Los Reyes Pascual PérezJosé López CastroJosé Luis Serrano Carrillo de AlbornozJosé F VaronaRicardo Gómez-HuelgasJuan-Miguel Antón-SantosCarlos Lumbreras-BermejoPublished in: Canadian journal of respiratory therapy : CJRT = Revue canadienne de la therapie respiratoire : RCTR (2024)
Patients with chronic inhaled corticosteroids had longer hospital stays and more chronic comorbidities, measured by the Charlson comorbidity index, but they did not have more severe disease at admission, evaluated with qSOFA and PSI scores. Chronic treatment with inhaled corticosteroids had no influence on the prognosis of patients with chronic lung disease and COVID-19.